SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending after securing Japanese marketing approval for its groundbreaking Alpha DaRT technology, which the community views as a significant global validation and de-risking event. This, alongside strong financial reports and imminent clinical trial readouts, is fueling widespread bullish sentiment and discussions of its undervaluation and substantial upside potential.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending due to its aggressive expansion into defense technology with recent strategic acquisitions, including BIRD Aerosystems for missile protection and a merger with Mistral Inc., complemented by new multi-million dollar counter-drone system orders. The market is keenly watching whether these moves will catalyze significant revenue growth and a short squeeze, or if ongoing share dilution will continue to temper price action.

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Incannex Healthcare Limited - ADR

Incannex Healthcare is trending as it approaches Nasdaq compliance following its recent reverse split, a key de-risking event that has ignited community discussion around its low float. Investors are eagerly anticipating imminent FDA End-of-Phase 2 feedback for its promising IHL-42X sleep apnea drug, fueling speculation of a potential short squeeze and significant upside.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is actively discussed following its first GAAP profitable quarter, strong Q4 performance, and a new $500M stock buyback, with bulls optimistic about its Agentic AI direction and potential government contracts, while others express concern over conservative revenue guidance.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is trending amidst a barrage of new strategic partnerships with key players across defense, energy, AI infrastructure, and commercial sectors, including Centrus, Ondas, GE Aerospace, Nvidia, LG, and Polymarket. The community is buzzing about the broad applicability of Palantir's AI-driven platforms, driving discussion on its expanding influence in both government and enterprise operations.

Smart Lending AI (SLAI) is a decentralized on-chain lending protocol that lets users lock approved tokens and instantly borrow up to 50% of their USD value in ETH—without selling. Prices are calculated directly on-chain via WETH pairs, and loan risk is managed through real-time volatility and liquidity analysis. Borrowers pay a flat 5% interest, while SLAI stakers (≥50,000 tokens) enjoy zero interest benefits. Designed for active DeFi traders, SLAI enables fast, gas-efficient liquidity access while preserving token exposure.

Smart Lending AI

Smart Lending AI (SLAI) is trending after receiving a preliminary going-private proposal offering a premium over its recent trading prices, sparking community debate over a potential low-ball buyout and a significant shift in voting power to its founder. This is compounded by discussions around a strategic pivot into AI and blockchain, adding to investor interest.

Dollar General Corp. engages in the operation of merchandise stores. Its offerings include food, snacks, health and beauty aids, cleaning supplies, basic apparel, housewares, and seasonal items. It sells brands including Clorox, Energizer, Procter & Gamble, Hanes, Coca-Cola, Mars, Unilever, Nestle, Kimberly-Clark, Kellogg's, General Mills, and PepsiCo. The company was founded by J. L. Turner and Hurley Calister Turner Sr. in 1939 and is headquartered in Goodlettsville, TN.

Dollar General Corp.

Dollar General is a trending topic as investors grapple with its stock movement following a quarterly earnings beat, sparking community discussion on why shares declined despite strong results and how its value-driven model performs amid evolving consumer habits and operational adjustments.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending due to persistent acquisition rumors from major pharmaceutical companies like Eli Lilly and AstraZeneca, fueled by reports from a reputable French publication, highlighting its promising ulcerative colitis treatment and robust clinical data. The community is actively discussing a potential bidding war given the drug's innovative profile and upcoming data presentations, positioning it as a highly attractive target in the biotech sector.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating Middle East tensions and reported attacks on oil tankers near the Strait of Hormuz are driving a sharp rise in crude oil prices, as the community debates whether strategic reserve releases can effectively counter the ongoing supply risks.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing strong momentum following its development agreement with Tower Semiconductor to integrate its electro-optic polymer modulators into Tower's silicon photonics platform. The community is buzzing with excitement, viewing this collaboration as a major validation and a crucial step towards scalable manufacturing for high-speed AI and data center infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sangamo Therapeutics (SGMO) to Release Earnings on Monday

Sangamo Therapeutics (NASDAQ:SGMO) will be releasing its Q4 2025 earnings before the market opens on Monday, March 16. (View Earnings Report at...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) saw a significant growth in short interest in February. As of February 13th, there was short interest totaling 33,200,460 shares, a growth...

FY2030 Earnings Forecast for SGMO Issued By HC Wainwright

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a report issued on Tuesday...

Sangamo Therapeutics (NASDAQ:SGMO) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen downgraded shares of Sangamo Therapeutics to a "strong sell" rating in a report on Saturday...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Hold" from Brokerages

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has been given a consensus recommendation of "Hold" by the seven ratings firms that are presently covering the firm, MarketBeat Ratings...

Sangamo Therapeutics (NASDAQ:SGMO) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Sangamo Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Saturday...

Research Analysts Offer Predictions for SGMO FY2025 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright decreased their FY2025 earnings per share estimates for Sangamo Therapeutics in a report released on Monday, November 10th. HC...

Q4 Earnings Forecast for SGMO Issued By HC Wainwright

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright issued their Q4 2025 earnings estimates for shares of Sangamo Therapeutics in a note issued to investors on Monday, November...

Sangamo Therapeutics (NASDAQ:SGMO) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus...

Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -266.67% and -98.84%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

SGMO
Sangamo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMO News

SGMOSangamo Therapeutics Inc